A retrospective discussion of the prognostic value of combining prothrombin time(PT) and fibrinogen(Fbg) in patients with Hepatocellular carcinoma

被引:33
作者
Wang, Xue-Ping [1 ]
Mao, Min-Jie [1 ]
He, Zhong-Lian [2 ]
Zhang, Lin [1 ,3 ]
Chi, Pei-Dong [1 ]
Su, Jia-rui [4 ]
Dai, Shu-Qin [1 ]
Liu, Wan-Li [1 ]
机构
[1] Sun Yat Sen Univ, Canc Ctr, Collaborat Innovat Ctr Canc Med, Dept Lab Med,State Key Lab Oncol South China, Guangzhou 510060, Guangdong, Peoples R China
[2] Sun Yat Sen Univ, Canc Ctr, Collaborat Innovat Ctr Canc Med, Dept Informat Sect,State Key Lab Oncol South Chin, Guangzhou 510060, Guangdong, Peoples R China
[3] Guangdong Esophageal Canc Inst, Guangzhou, Guangdong, Peoples R China
[4] Guangdong Med Univ, Guangzhou 523808, Guangdong, Peoples R China
来源
JOURNAL OF CANCER | 2017年 / 8卷 / 11期
关键词
HCC; prothrombin time; fibrinogen; prognosis; overall survival; disease-free survival; TISSUE FACTOR; TUMOR-CELLS; LUNG-CANCER; HEMOSTASIS; PROGRESSION; THROMBOSIS; MELANOMA;
D O I
10.7150/jca.19181
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aims: The levels of coagulation system tests have been studied in various cancers. In this study, our aim is to evaluate the prognostic value of pretreatment plasma coagulation tests in hepatocellular carcinoma (HCC) patients. Patient and methods: A retrospective study was performed in 539 patients with HCC, and follow-up period was at least 60 months until recurrence or death. The prognostic significance of coagulation system tests (prothrombin time, activated partial thromboplastin time, thrombin time, fibrinogen) were determined by univariate and multivariate Cox hazard models. Then, according to the results of the multivariate analyses, we proposed the coagulation-Based Stage, which combined the independent risk factors (prothrombin time and fibrinogen). Results: Coagulation system tests including prothrombin time (PT), activated partial thromboplastin time (APTT), thrombin time (TT), fibrinogen (Fbg) were analyzed. Patients with prolonged PT (>= 12.1 sec) levels had significantly poor overall survival (OS) and disease-free survival (DFS), not only in the entire cohort (HR: 1.661, 95% CI: 1.125-2.451, p=0.011 vs. HR: 1.660, 95% CI: 1.125-2.451, p=0.011), but also in the subgroups stratified by pathological stage (stage I-II and stage III-IV). Additionally, high Fbg (>= 2.83 g/L) levels experienced significantly decreased OS and DFS (HR: 2.158, 95% CI: 1.427-3.263, p<0.001 vs. HR: 2.161, 95% CI: 1.429-3.267, p<0.001), not only in the entire cohort but also in the subgroups stratified by pathological stage (stage I-II and stage III-IV). All the patients were then stratified (based on combined PT and Fbg) into three groups, The OS for HCC patients were (41.37 +/- 17.76), (31.83 +/- 19.84) and (18.68 +/- 18.41) months, and the DFS for HCC patients were (41.15 +/- 17.88), (31.65 +/- 19.81) and (18.66 +/- 18.39) months. Conclusions: Our findings suggest that the combination of plasma PT and Fbg levels should be evaluated as the valuable predictor of survival in patients with HCC.
引用
收藏
页码:2079 / 2087
页数:9
相关论文
共 30 条
  • [1] The role of tissue factor pathway inhibitor in tumor growth and metastasis
    Amirkhosravi, Ali
    Meyer, Todd
    Amaya, Mildred
    Davila, Monica
    Mousa, Shaker A.
    Robson, Theresa
    Francis, John L.
    [J]. SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2007, 33 (07) : 643 - 652
  • [2] [Anonymous], ONCOTARGET
  • [3] Hemostasis and global fibrinolytic capacity in chronic liver disease
    Aytac, Sirin
    Turkay, Cansel
    Bavbek, Nuket
    Kosar, Ali
    [J]. BLOOD COAGULATION & FIBRINOLYSIS, 2007, 18 (07) : 623 - 626
  • [4] Hypercoagulability and hyperfibrinolysis in patients with melanoma
    Bottasso, B
    Mari, D
    Coppola, R
    Santoro, N
    Vaglini, M
    Mannucci, PM
    [J]. THROMBOSIS RESEARCH, 1996, 81 (03) : 345 - 352
  • [5] Haemostatic and inflammatory biomarkers in advanced chronic heart failure: role of oral anticoagulants and successful heart transplantation
    Cugno, M
    Mari, D
    Meroni, PL
    Gronda, E
    Vicari, F
    Frigerio, M
    Coppola, R
    Bottasso, B
    Borghi, MO
    Gregorini, L
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2004, 126 (01) : 85 - 92
  • [6] DITTMAN WA, 1990, BLOOD, V75, P329
  • [7] DONATI MB, 1986, CANCER RES, V46, P6471
  • [8] Rising incidence of hepatocellular carcinoma in the United States
    El-Serag, HB
    Mason, AC
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (10) : 745 - 750
  • [9] Thrombophilia in cancer
    Falanga, A
    [J]. SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2005, 31 (01) : 104 - 110
  • [10] Falanga Anna, 2003, Clin Adv Hematol Oncol, V1, P673